AZD4045 vs HRC0202

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: BCMA · full Multiple Myeloma pipeline

AZD4045

Developed by AstraZeneca

Phase 1/2 in Multiple Myelomaallogeneic CAR-T cell therapy (anti-BCMA)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: March 2031 · NCT07681596 (registry estimate)

No aligned efficacy figure on record for this race.

HRC0202

Developed by Hrain Biotechnology Co., Ltd.

Phase 2 in Multiple MyelomaCAR-T (autologous, BCMA-directed)
Weak signal

NCT04003168 · Phase 1 · status unknown

This is a small, single-arm, open-label safety study with no control group, so it cannot show whether the therapy works better than an alternative. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

The published report covers seven treated patients, fewer than the study's listed enrollment.

Reported efficacy

Number of participants with treatment-related adverse events as assessed by NCI-CTCAE 5.0 (28 days post infusion): In seven patients with relapsed/refractory multiple myeloma previously treated with anti-BCMA CAR-T (four relapsed, three refractory), the best overall response rate was 71.4% (5/7), with stringent complete response or complete response achieved in three patients. Cytokine release syndrome of grades 1-2 occurred in three patients (42.9%) and grade >=3 in two patients (28.6%).

Result source: NCT04003168

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAZD4045HRC0202
PFS, median—Not reported—Not reported
OS, median—Not reported—Not reported
ORR—Not reported—Not reported
VGPR or better—Not reported—Not reported
MRD negativity—Not reported—Not reported

PFS, median

AZD4045
—Not reported
HRC0202
—Not reported

OS, median

AZD4045
—Not reported
HRC0202
—Not reported

ORR

AZD4045
—Not reported
HRC0202
—Not reported

VGPR or better

AZD4045
—Not reported
HRC0202
—Not reported

MRD negativity

AZD4045
—Not reported
HRC0202
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

AZD4045: no structured comparison results are available for Multiple Myeloma.

HRC0202: no structured comparison results are available for Multiple Myeloma.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AZD4045's landscape · HRC0202's landscape